The patient, whose primary tumor expressed high levels of PDL-1, displayed rapid and complete disease resolution following nivolumab administration and has since shown no evidence of disease recurrence by PET/CT for 22 months following complete response. This evidence concerns the gene CD274 and neoplasm.